Trial Profile
Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2017
Price :
$35
*
At a glance
- Drugs Fludarabine (Primary) ; Antithymocyte globulin; Ciclosporin; Cyclophosphamide
- Indications Graft-versus-host disease; Haematological malignancies
- Focus Therapeutic Use